Efficacy and safety of prostate radiotherapy in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer

Christopher J. Sweeney, Yu‐Hui Chen, Michael A. Carducci et al. · New England Journal of Medicine · 2015 · 2.8K citations · Full text

Medicine, Oncology, Urology +15

Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group

Howard I. Scher, Susan Halabi, Ian F. Tannock et al. · Journal of Clinical Oncology · 2008 · 2.2K citations · Full text

Medicine, Oncology, Urology +17

Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer

Karim Fizazi, NamPhuong Tran, Luis Fein et al. · New England Journal of Medicine · 2017 · 2.2K citations · Full text

Medicine, Oncology, Pharmacotherapy +15

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial

Nicholas D. James, Matthew R. Sydes, Noel W. Clarke et al. · The Lancet · 2015 · 2K citations · Full text

Medicine, Oncology, Urology +17

Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy

Nicholas D. James, Johann S. de Bono, Melissa Spears et al. · New England Journal of Medicine · 2017 · 1.8K citations · Full text

Medicine, Oncology, Urology +14